-
Thierry Diagana and his team are on a quest to discover new therapeutics for malaria. He believes malaria elimination is within our grasp, but emerging drug resistance could jeopardize the hard-fought progress.
Access to HealthcareInfectious DiseasesMalariaMedical InnovationsTropical Diseases -
Chronic IllnessEnvironmental SustainabilityInfectious DiseasesMalariaNovartis Institutes for BioMedical Research
-
Basel, December 14, 2020 — Novartis today announced that the Phase III RUXCOVID study evaluating ruxolitinib on top of standard of care (SoC) therapy compared to SoC treatment alone in patients with COVID-19 did not meet its primary endpoint1. Initial data show there was no statistically significant reduction in the proportion of patients on…Infectious DiseasesEthical Business
-
Basel, March 4, 2021 — Novartis announced today that it has signed an initial agreement to manufacture the mRNA and bulk drug product for the COVID-19 vaccine candidate CVnCoV from CureVac to aid in the fight against the COVID-19 pandemic. Preparations for the start of production, technology transfer and test runs are already underway. Following…Reimagine MedicineInfectious Diseases
-
Basel, October 28, 2020 — Novartis and Molecular Partners AG today announced a collaboration in the form of an option and license agreement to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19 DARPin® program, consisting of two therapeutic candidates, MP0420 and MP0423. The collaboration aims to leverage Molecular Partners’…Reimagine MedicineInfectious DiseasesGlobal Health PartnershipsBiomedical Research
-
Basel, December 14, 2020 — Novartis today announced that the Phase III RUXCOVID study evaluating ruxolitinib on top of standard of care (SoC) therapy compared to SoC treatment alone in patients with COVID-19 did not meet its primary endpoint1. Initial data show there was no statistically significant reduction in the proportion of patients on…Infectious DiseasesEthical Business
-
Basel, March 4, 2021 — Novartis announced today that it has signed an initial agreement to manufacture the mRNA and bulk drug product for the COVID-19 vaccine candidate CVnCoV from CureVac to aid in the fight against the COVID-19 pandemic. Preparations for the start of production, technology transfer and test runs are already underway. Following…Reimagine MedicineInfectious Diseases
-
Basel, April 2, 2020 — Novartis today announced plans to initiate a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi® (ruxolitinib) for treatment of a type of severe immune overreaction called cytokine storm that can lead to life-threatening respiratory complications in patients with COVID-191-3.Social CommitmentInfectious DiseasesGlobal Health Partnerships
-
Basel, April 20, 2020 — Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial with approximately 440 patients to evaluate the use of hydroxychloroquine for the treatment of hospitalized patients with COVID-19 disease. The clinical trial drug supply will be provided by Sandoz,…Social CommitmentScientific ResearchInfectious Diseases
-
Holzkirchen, July 27, 2020 – Sandoz, the Novartis generics and biosimilars division, is pleased to announce plans for a joint investment, together with the Austrian federal government, to strengthen the long-term future of integrated antibiotics manufacturing in Europe.Social CommitmentInfectious DiseasesAccess to Healthcare
-
Healthcare worker Dismus Mwalukwanda is on the front line of the battle against malaria. Saving lives is his priority.
Access to HealthcareDisease EradicationInfectious DiseasesMalariaNovartis Social BusinessTropical Diseases -
Paul Aliu and his team quickly address requests for Novartis medicines during the pandemic.
COVID-19Infectious DiseasesInnovationWorking at Novartis
Pagination
- 1
- 2
- 3
- › Next page